Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0H4WH
|
||||
| Former ID |
DNC004726
|
||||
| Drug Name |
Des-AA5-[D-Trp8]SRIF
|
||||
| Indication | Discovery agent | Investigative | [539293] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C72H98N16O17S2
|
||||
| Canonical SMILES |
CC(C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O<br />)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=C<br />C=C32)CC4=CC=CC=C4)CC5=CC=CC=C5)CCCCN)NC(=O)CNC(=O)C(C)<br />N)C(=O)O)CO)C(C)O)CC6=CC=CC=C6)O
|
||||
| InChI |
1S/C72H98N16O17S2/c1-40(75)61(93)77-36-58(92)78-56-38-106-107-39-57(72(104)105)86-68(100)55(37-89)85-71(103)60(42(3)91)88-67(99)53(33-45-23-11-6-12-24-45)84-70(102)59(41(2)90)87-63(95)50(28-16-18-30-74)79-66(98)54(34-46-35-76-48-26-14-13-25-47(46)48)83-65(97)52(32-44-21-9-5-10-22-44)82-64(96)51(31-43-19-7-4-8-20-43)81-62(94)49(80-69(56)101)27-15-17-29-73/h4-14,19-26,35,40-42,49-57,59-60,76,89-91H,15-18,27-34,36-39,73-75H2,1-3H3,(H,77,93)(H,78,92)(H,79,98)(H,80,101)(H,81,94)(H,82,96)(H,83,97)(H,84,102)(H,85,103)(H,86,100)(H,87,95)(H,88,99)(H,104,105)/t40-,41+,42+,49+,50-,51+,52-,53-,54-,55-,56+,57-,59+,60+/m0/s1
|
||||
| InChIKey |
ZIHRAPFYJSDXSV-BVGUNDCQSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Somatostatin receptor 1 | Target Info | Inhibitor | [527384] | |
| Somatostatin receptor type 2 | Target Info | Inhibitor | [527384] | ||
| Somatostatin receptor type 4 | Target Info | Inhibitor | [527384] | ||
| Somatostatin receptor type 5 | Target Info | Inhibitor | [527384] | ||
| Somatostatin receptor type 3 | Target Info | Inhibitor | [527384] | ||
| KEGG Pathway | cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interactionhsa04024:cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Gastric acid secretionhsa04080:Neuroactive ligand-receptor interactionhsa04024:cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interactionhsa04080:Neuroactive ligand-receptor interaction | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| PathWhiz Pathway | Gastric Acid Production | ||||
| WikiPathways | SIDS Susceptibility Pathways | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP706:SIDS Susceptibility Pathways | |||||
| GPCR downstream signaling | |||||
| GPCRs, OtherWP455:GPCRs, Class A Rhodopsin-like | |||||
| GPCR downstream signalingWP455:GPCRs, Class A Rhodopsin-like | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.